Bedrijfsoverzicht
Benitec Biopharma Inc. is a clinical-stage biotechnology entity dedicated to the development of novel genetic medicines, specifically utilizing its Silence and Replace DNA-directed RNA interference platform to combine RNA interference with gene therapy for sustained silencing. The company operates within the healthcare sector, specifically the biotechnology industry, where it focuses on advancing therapies that address complex medical conditions through genetic intervention. Its current market capitalization stands at $391.19M, while the firm employs 19 individuals to execute its research and development strategies. The market cap figure indicates that the company is a relatively small-cap entity within the broader biotechnology landscape, operating with limited revenue generation typical of pre-commercial clinical-stage firms.
Financiële gezondheid
The company reports no annual revenue data (N/A), with a net income (TTM) of $-44,108,000 and an EBITDA of $-48,295,000, revealing a cost structure dominated by high operating expenses associated with clinical trials and R&D rather than sales costs. Free cash flow stands at $-4,355,125, indicating that the company is burning cash to fund its operations and development pipeline, which limits immediate financial flexibility without external capital injection. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is characteristic of early-stage biotechnology companies that have not yet achieved commercial sales to generate revenue-based profitability. The company holds $188.79M in cash against total debt of $987,000, resulting in a debt-to-equity ratio of 0.53, which suggests a balance sheet that is not leveraged but rather heavily cash-rich relative to its obligations. The current ratio is an exceptionally high 67.69, indicating robust short-term liquidity and the ability to cover current liabilities many times over with available assets. Return on Equity is -33.5% and Return on Assets is -22.4%, metrics that reveal management is currently deploying capital to generate negative returns due to the lack of commercial revenue streams typical of the clinical development phase.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the absence of positive earnings, while the forward P/E is -1.21, implying that the market is pricing in future earnings potential that has not yet materialized in current financial statements. The price-to-book ratio is 2.09, indicating that the market values the company's equity at more than double its book value, a premium often seen in biotech firms with valuable intellectual property portfolios. Alternative valuation metrics such as the price-to-sales ratio (N/A) and EV/EBITDA of -4.24 suggest that traditional valuation multiples are not applicable due to the lack of revenue and earnings, necessitating reliance on asset-heavy or pipeline-based assessments. The stock's 52-week high is $17.15 and the 52-week low is $9.85, with the current trading price situated within this range reflecting recent market sentiment volatility. The beta value of 0.12 indicates that the stock price exhibits significantly lower volatility than the broader market, behaving in a manner more akin to a low-beta defensive asset despite its biotechnology sector classification.
Growth & Income
Revenue growth year-over-year is N/A, and earnings growth year-over-year is also N/A, meaning that conventional growth rate comparisons are unavailable for this clinical-stage company due to the absence of a historical commercial sales base. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash is retained to fund operations and development rather than distributed. This reinvestment strategy is standard for clinical-stage biotechnology firms that prioritize capital allocation toward advancing their Silence and Replace platform over providing income returns to investors. The overall growth and income profile is characterized by significant cash reserves and a lack of current profitability, with future growth dependent entirely on the successful progression of clinical trials and eventual regulatory approval of its genetic medicine candidates.